Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseases: Likelihood of Approval

Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and Co and currently in Phase I for Neurodegenerative Diseases.

Lonza taps Siegfried leader Wolfgang Wienand as new CEO

Lonza named Wolfgang Wienand as its new CEO on Tuesday morning, replacing interim leader Albert Baehny this summer. Wienand has been with the CDMO Siegfried

April 3, 2024

Grading The Week: Broncos’ midseason MVP? These scouts say it’s safety Brandon Jones – The Cannabist

Miss Justin Simmons? The kids on the Grading The Week staff sure do, but the Broncos don’t. Not according to Pro Football Focus, at least.

November 2, 2024

Canada Approves First Legal Medical Psilocybin Access Via Apex’s Macrodose Therapy

Health Canada’s Special Access Program (SAP) has authorized a physician to provide Apex Labs’ psilocybin macrodose drug protocol to patient Kelsi Sheren, a Canadian Armed Forces veteran, as therapy

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.